Infographic : Brooks Labrotories (NSE : BROOKS) | Q4FY22 Results Released! | Revenue UP 94.55% YoY

Brooks Laboratories Ltd is a pharmaceutical contract manufacturing company. The company has manufacturing facilities in Baddi Himachal Pradesh and Vadodara Gujarat. Both units are cGMP compliant in accordance with national and international standards.

The Vadodara facility has been approved by the European Medicines Agency. The company has a wide range of products for the critical care segment in the parenteral section such as Beta Lactam Cephalosporin and generic dry powder injection ampoules and liquid vials Dry syrups and tablets etc.

Their product portfolio currently includes 28 injectables 19 tablets and 2 dry syrups that are sold on the domestic market. The company’s manufacturing facilities are designed to manufacture various products in the formula segment using a combination of processes. V Baddi manufactures a wide range of products in the formulation segment for various top companies in India.

The company’s total revenue on a consolidated basis for the quater ended March 31, 2022 stood at Rs 28.6 Crore, an increase of 94.55 % over the previous year. The company’s operating expenses on a consolidated basis for the quater ended March 31, 2022 stood at Rs 32.4 Crore, an increase of 75.13 % over the Previous Year.

Loss before tax is Rs 6.5 Crore, an increase of 79.19 % over the previous year. EPS on a consolidated basis for the quater ended March 31, 2022 stood at Rs 1.5, an increase of 11.53 % over the Previous Year.